Navigation Links
Nuvilex to Issue Positive Shareholder Newsletter
Date:8/25/2009

CHERRY HILL, N.J., Aug. 25 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), announces today that it will issue a shareholder newsletter on September 1, 2009. Additionally, regional shareholder meetings will be held in New York City on September 16th, Chicago on September 17th, and Los Angeles on September 18th. Regional shareholder meeting times and locations will be announced on or before September 7, 2009.

"We are very aware of our shareholders' interest in our business endeavors," stated Martin Schmieg, Chairman and Chief Executive Officer of Nuvilex, Inc. "Like all public companies, the accounting and legal requirements of what we can and must say in our annual and quarterly SEC filings often times paints a less than favorable picture of the positive progress the Company is making in product development, marketing and sales and improving its financial condition."

"Nuvilex is a Company with great promise and a strong future," continued Schmieg. Unlike most development and early revenue stage companies who typically have a single technology or product, Nuvilex has ten unique product opportunities in four diverse markets.

The current business challenge facing Nuvilex is successfully marketing the company's high quality, differentiated and competitively priced products. "We believe these products will become highly sought after, but this will only happen after consumers become aware that our products exist and can be easily obtained," said Schmieg. "This requires building brand awareness and distribution channels."

As a small company, Nuvilex, plans to market the Company's products effectively and efficiently without raising large sums of money (highly dilutive) through the following three-part business strategy:

  1. Focus on short-term successes that can maximize and drive immediate revenue growth and cash in-flows. Presently the Last Shot Hangover Remedy, Prevorex and the Company's cosmetics and skin care products are well suited as "Quick Strike" products. Quick Strike products are those that can effectively market either directly or indirectly developing brand awareness and wide distribution within twelve to eighteen months. To financially support our Quick Strike products, the sale of certain product marketing and/or distribution rights, for example international market rights, may be necessary.
  2. Partnering for long-term success. Currently we have a partner, a multi-billion dollar private agricultural products company, who will be assisting us with the final phases of development and commercialization of Oraphyte for the turf grass industry. We are currently discussing a co-development and commercialization contract for crop protection with a Fortune 100 company. Commercial partners can hasten, through their experience and established market position, product development, introduction and global sales penetration. There is, however, a corresponding cost. If we assume that our partners will bear substantially all of the brand development and distribution costs, our share of the revenues and profits from partnered products will be substantially lower than non-partnered products. We believe, however, for products like Oraphyte maximum market penetration can only be achieved through partnerships with established companies.
  3. Out-license to financially support more robust opportunities. As previously identified, our challenge is to become a skilled marketing company. This will require us to hire talented people and/or engage outside resources in support of building and executing effective marketing programs. Within our product and technology portfolio, we have intellectual property (patents) and product assets of value that could be either sold or licensed. The proceeds from these activities, which typically include milestone and royalty payments, would support the marketing programs of retained products and potentially build up the balance sheet.

"Performance is the key to our success. Product performance, market performance, revenue performance, profit performance and management performance will drive Nuvilex' value, your return on investment," stated Schmieg. "Nuvilex has and continues to be successful at building outstanding products. The Company's next challenge is market performance. Market performance will be achieved by putting in place the resources, human and financial, that are needed to build brand awareness and distribution of our products. As consumers become aware of our products, revenue and profit performance will follow. Management is committed and dedicated to implementing and executing business strategies that are achievable and measurable."

The management of Nuvilex believes that the stage is set for Company's future. In collaboration with its major shareholders, Nuvilex has secured non-dilutive financing to ensure the Company has sufficient time to achieve its short-term marketing and sales goals and conclude its current business development activities -- partnership and out-licensing negotiations.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy, a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen, which promotes a healthy glucose metabolism; Cinnechol, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink( (R)), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink( (R)). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Company Contact:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex Completes First Sale of Last Shot Hangover Remedy(TM)
2. Nuvilex, Inc. Announces Business Update Conference Call
3. Nuvilex Cites Study that Suggests Red Yeast Rice, an Active Ingredient in Cinnechol, Can Help to Improve Cardiovascular Health
4. Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream
5. Nuvilex Featured in Wall Street Reporter Interview
6. Nuvilex Offers Free Cinnergen Samples in Response to Spike in Consumer Interest
7. Nuvilex Launches Video Marketing Campaign
8. Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan
9. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
10. Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex
11. Nuvilex, Inc. Announces Monthly Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology: